"Designing Growth Strategies is in our DNA"
Region : Global | Published Date: Upcoming | Report ID: FBI101276| Status : Pipeline
Contact dermatitis is a type of skin inflammation caused by an allergic reaction due to contact with a substance. Symptoms of this most common form of eczema include a red rash, blisters, itching, swelling or burning sensation. There are many allergens that can trigger contact dermatitis like, soap, nickel metal, cosmetics, therapeutic ointment, acid burns, diapers among others. There are currently two forms of contact dermatitis, allergic contact dermatitis caused due to an allergic reaction to a substance and irritant contact dermatitis caused due to exposure to toxic chemicals.
Since contact dermatitis is curable skin eczema and the treatment options comprises of medications applied topically and in severe cases administered orally. Oral antihistamine drugs like cetirizine and fexofenadine are prescribed to treat contact dermatitis. In the majority of the cases, corticosteroid ointment is applied to alleviate the skin inflammation.
Research institutes and pharmaceutical companies are developing various treatment options form contact dermatitis most of which have completed their clinical studies. For instance, Innovaderm Research Inc. is currently studying EB01 Cream which is in Phase 2 clinical trial for the treatment of chronic allergic contact dermatitis.
At present, around 50% of the pipeline candidates for contact dermatitis are in the phase-2 clinical stage. More than half of the studies are sponsored by industry.
The report on ‘Contact Dermatitis – Pipeline Review, 2019’ provides a comprehensive overview of the drugs that are in the R&D pipeline by indication or molecule for contact dermatitis. The report provides a thorough analysis of the distribution of the pipeline products by clinical trial stage, indication, company, therapy area and details such as clinical trial stage, sponsor, description on every product in the pipeline. Products in the preclinical and clinical stage along with dormant & discontinued pipeline candidates are included in the report. The report also covers additional insights such as epidemiology overview and current market scenario for contact dermatitis.
The report on ‘Contact Dermatitis – Pipeline Review, 2019’, which is built by following a robust research methodology involving primary interviews and desk research, provides a complete overview of the R&D activity and pipeline products to assist companies in developing growth strategies and identifying emerging players.